Neurology

Back to articles

Rituximab an option for secondary progressive MS

KEY POINT

Patients with secondary progressive multiple sclerosis (MS), an advanced form of MS, who were treated with rituximab had significantly lower scores on the Expanded Disability Status Scale (EDSS) and a significantly delayed time to confirmed progression compared with patients not given rituximab, according to results of an observational study published in JAMA Neurology.